HALO AP® Deep Bio Case Study
Discover how the seamless integration of third-party image analysis algorithms, such as DeepDx from Deep Bio, with HALO AP® can benefit your lab.
HALO AP® Deep Bio Case Study Read More »
HALO AP
Automated PD-L1 Tumor Proportion Scoring Algorithm in Non-Small Cell Lung Cancer for Multiple Companion Diagnostic Assays
Read about the development and validation of an AI-based PD-L1 scoring algorithm for HALO AP®.
Development & Validation of an AI-based Tumour Cell Estimation Algorithm for Use in a Lung Adenocarcinoma Molecular Pathology Workflow
Learn more about the development and validation of an AI-based molecular pathology algorithm for estimating tumour cells in lung adenocarcinoma.
Development & Validation of an AI-based Workflow for Clinical Scoring of HER2, ER, PR, & Ki67 Immunohistochemistry in Breast Cancer Tissue
Explore Breast IHC AI, a deep learning-based workflow for evaluation of breast cancer.
HALO AP® 2.4 Features and Functionalities
Check-out exciting new features and functionalities in the latest release of HALO AP®, AI-powered digital pathology platform for diagnostics
HALO AP® 2.4 Features and Functionalities Read More »
Migrating from Aperio eSlide Manager to Indica Labs HALO Image Management Systems
Migrating from Aperio eSlide Manager to Indica Labs HALO Image Management Systems
Migrating from Aperio eSlide Manager to Indica Labs HALO Image Management Systems Read More »
ECDP 2025
26 – 28 June 2025 | Visit us at booth #19 for a live demonstration of the latest developments across our HALO clinical and life science products on June 26-28 or prebook a meeting at our booth.
Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.
Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI
Albuquerque, NM, April 17, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today the expansion of their macrodissection suite with the launch of CRC Macrodissect AI. This expanded portfolio of AI powered tools by Indica Labs will facilitate a macrodissection workflow that minimizes human error and improves efficiency across multiple disease sites. Utilizing the integrative power of artificial intelligence and digital pathology, CRC Macrodissect AI will advance the field of molecular pathology and offer unparalleled insight into colorectal carcinoma.
Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI Read More »
Indica Labs’ Boston HALO® User Group Meeting
15 May 2025 | Indica Labs is pleased to announce our Boston HALO® User Group Meeting at Le Méridien Boston Cambridge on May 15 from 9:30 am – 4 pm.
Indica Labs’ Boston HALO® User Group Meeting Read More »